Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines

참고문헌 (128)

1. Doherty, M., "Vaccine impact : benefits for human health", Vaccine, 34, pp.6707~6714 (2016)
2. Rappuoli, R., "Vaccines for the twenty-first century society", Nat. Rev. Immunol, 11, pp.865~872 (2011)
3. Brisse, M., "Emerging concepts and technologies in vaccine development", Front. Immunol, 11, pp.583077~ (2020)
4. Kennedy, R. B., "Current challenges in vaccinology", Front. Immunol, 11, pp.1181~ (2020)
5. Kis, Z., "Rapid development and deployment of high-volume vaccines for pandemic response", J. Adv. Manuf. Process, 2, pp.e10060~ (2020)
6. Lorentzen, C. L., "Clinical advances and ongoing trials on mRNA vaccines for cancer treatment", Lancet Oncol, 23, pp.e450~e458 (2022)
7. Miao, L., "mRNA vaccine for cancer immunotherapy", Mol. Cancer, 20, pp.41~ (2021)
8. Chen, J., "Current developments and challenges of mRNA vaccines", Annu. Rev. Biomed. Eng, 24, pp.85~109 (2022)
9. Baden, L. R., "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine", N. Engl. J. Med, 384, pp.403~416 (2021)
10. Polack, F. P., "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine", N. Engl. J. Med, 383, pp.2603~2615 (2020)
11. Thi, T. T. H., "Lipid-based nanoparticles in the clinic and clinical trials : From cancer nanomedicine to COVID-19 vaccines", Vaccines(Basel), 9, pp.359~ (2021)
12. Andries, O., "N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice", J. Control Release, 217, pp.337~344 (2015)
13. Hogan, M. J., "mRNA vaccines in the COVID-19 pandemic and beyond", Annu. Rev. Med, 73, pp.17~39 (2022)
14. Buschmann, M. D., "Nanomaterial delivery systems for mRNA vaccines", Vaccines(Basel), 9, pp.65~ (2021)
15. Hassett, K. J., "Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines", Mol. Ther. Nucleic Acids, 15, pp.1~11 (2019)
16. Kanekiyo, M., "New vaccine design and delivery technologies", J. Infect. Dis, 219, pp.S88~S96 (2019)
17. Montagnon, B. J., "Polio and rabies vaccines produced in continuous cell lines : a reality for Vero cell line", Dev. Biol. Stand, 70, pp.27~47 (1989)
18. Gerdil, C., "The annual production cycle for influenza vaccine", Vaccine, 21, pp.1776~1779 (2003)
19. Pardi, N., "mRNA vaccines—a new era in vaccinology", Nat. Rev. Drug Discov, 17, pp.261~279 (2018)
20. Wu, F., "A new coronavirus associated with human respiratory disease in China", Nature, 579, pp.265~269 (2020)
21. Jackson, L. A., "An mRNA vaccine against SARS-CoV-2-preliminary report", N. Engl. J. Med, 383, pp.1920~1931 (2020)
22. Amanna, I. J., "Successful vaccines", Curr. Top. Microbiol. Immunol, 428, pp.1~30 (2020)
23. Watson, O. J., "Global impact of the first year of COVID-19 vaccination : a mathematical modelling study", Lancet Infect. Dis, 22, pp.1293~1302 (2022)
24. Arunachalam, P. S., "Systems vaccinology of the BNT162b2 mRNA vaccine in humans", Nature, 596, pp.410~416 (2021)
25. Thomas, S. J., "Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months", N. Engl. J. Med, 385, pp.1761~1773 (2021)
26. Weisblum, Y., "Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants", Elife, 9, pp.e61312~ (2020)
27. Boutwell, C. L., "Viral evolution and escape during acute HIV-1 infection", J. Infect. Dis, 202, pp.S309~S314 (2010)
28. Wu, N. C., "Different genetic barriers for resistance to HA stem antibodies in influenza H3 and H1 viruses", Science, 368, pp.1335~1340 (2020)
29. Elsner, R. A, "Germinal center and extrafollicular B cell responses in vaccination, immunity, and autoimmunity", Immunity, 53, pp.1136~1150 (2020)
30. Goel, R. R., "Distinct antibody and memory B cell responses in SARS-CoV-2naive and recovered individuals following mRNA vaccination", Sci. Immunol, 6, pp.eabi6950~ (2021)
31. Sachinidis, A., "COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells", Int. J. Rheum. Dis, 25, pp.83~85 (2022)
32. Kingstad-Bakke, B., "Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants", Proc. Natl Acad. Sci. USA, 119, pp.e2118312119~ (2022)
33. Widge, A. T., "Durability of responses after SARS-CoV-2 mRNA-1273 vaccination", N. Engl. J. Med, 384, pp.80~82 (2021)
34. Greaney, A. J., "Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2infection", Sci. Transl. Med, 13, pp.eabi9915~ (2021)
35. Eyre, D. W., "Effect of Covid-19 vaccination on transmission of alpha and delta variants", N. Engl. J. Med, 386, pp.744~756 (2022)
36. Edara, V. V., "mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 omicron variant", Cell Rep. Med, 3, pp.100529~ (2022)
37. Oscherwitz, J., "The promise and challenge of epitope-focused vaccines", Hum. Vaccin. Immunother, 12, pp.2113~2116 (2016)
38. Woodruff, M. C., "B Cell competition for restricted T cell help suppresses rare-epitope responses", Cell Rep, 25, pp.321~327 (2018)
39. Boyoglu-Barnum, S., "Quadrivalent influenza nanoparticle vaccines induce broad protection", Nature, 592, pp.623~628 (2021)
40. Chalkias, S., "A bivalent omicron-containing booster vaccine against Covid-19", N. Engl. J. Med, 387, pp.1279~1291 (2022)
41. Goel, R. R., "mRNA vaccines induce durable immune memory to SARS-CoV-2and variants of concern", Science, 374, pp.abm0829~ (2021)
42. Khoury, D. S., "Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection", Nat. Med, 27, pp.1205~1211 (2021)
43. Barda, N., "Effectiveness of a third dose of the BNT162b2 mRNA COVID-19vaccine for preventing severe outcomes in Israel : an observational study", Lancet, 398, pp.2093~2100 (2021)
44. Taub, D. D., "Immunity from smallpox vaccine persists for decades : a longitudinal study", Am. J. Med, 121, pp.1058~1064 (2008)
45. Turner, J. S., "SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses", Nature, 596, pp.109~113 (2021)
46. Jenks, S. A., "Extrafollicular responses in humans and SLE", Immunol. Rev, 288, pp.136~148 (2019)
47. Rothaeusler, K., "B-cell fate decisions following influenza virus infection", Eur. J. Immunol, 40, pp.366~377 (2010)
48. Jenks, S. A., "Distinct effector B cells induced by unregulated Toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus", Immunity, 52, pp.203~ (2020)
49. Woodruff, M. C., "Dysregulated naive B cells and de novo autoreactivity in severe COVID-19", Nature, 611, pp.139~147 (2022)
50. Nguyen, D. C, "Factors affecting early antibody secreting cell maturation into long-lived plasma cells", Front. Immunol, 10, pp.2138~ (2019)
51. Pulendran, B., "Emerging concepts in the science of vaccine adjuvants", Nat. Rev. Drug Discov, 20, pp.454~475 (2021)
52. Kasturi, S. P., "Programming the magnitude and persistence of antibody responses with innate immunity", Nature, 470, pp.543~547 (2011)
53. Kim, E. H., "Squalene emulsion-based vaccine adjuvants stimulate CD8 T cell, but not antibody responses, through a RIPK3-dependent pathway", Elife, 9, pp.e52687~ (2020)
54. Lee, S. M., "Role of damage-associated molecular pattern", cell death pathways in vaccine-induced immunity, 2021, pp.13, 2340~
55. Li, C., "Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine", Nat. Immunol, 23, pp.543~555 (2022)
56. Alameh, M. G., "Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses", Immunity, 54, pp.2877~2892 (2021)
57. Bloom, K., "Self-amplifying RNA vaccines for infectious diseases", Gene Ther, 28, pp.117~129 (2021)
58. Britto, C., "The next frontier in vaccine design : blending immune correlates of protection into rational vaccine design", Curr. Opin. Immunol, 78, pp.102234~ (2022)
59. Plotkin, S. A., "Vaccines : correlates of vaccine-induced immunity", Clin. Infect. Dis, 47, pp.401~409 (2008)
60. Pulendran, B., "Immunological mechanisms of vaccination", Nat. Immunol, 12, pp.509~517 (2011)
61. Gilbert, P. B., "Immune correlates analysis of the mRNA-1273 COVID-19vaccine efficacy clinical trial", Science, 375, pp.43~50 (2022)
62. McMahan, K., "Correlates of protection against SARS-CoV-2 in rhesus macaques", Nature, 590, pp.630~634 (2021)
63. Keeton, R., "T cell responses to SARS-CoV-2 spike cross-recognize Omicron", Nature, 603, pp.488~492 (2022)
64. Shafqat, A., "Understanding COVID-19 vaccines today: Are T-cells key players?", Vaccines (Basel), 10, pp.904~ (2022)
65. Tarke, A., "SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron", Cell, 185, pp.847~859 (2022)
66. Victora, G. D., "Germinal centers", Annu. Rev. Immunol, 40, pp.413~442 (2022)
67. Crotty, S., "Follicular helper CD4 T cells(TFH)", Annu. Rev. Immunol, 29, pp.621~663 (2011)
68. Lindgren, G., "Induction of Robust B Cell responses after influenza mRNA vaccination is accompanied by circulating hemagglutinin-specific ICOS+ PD-1+CXCR3+ T follicular helper cells", Front. Immunol, 8, pp.1539~ (2017)
69. Pardi, N., "Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses", J. Exp. Med, 215, pp.1571~1588 (2018)
70. Corbett, K. S., "Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates", N. Engl. J. Med, 383, pp.1544~1555 (2020)
71. Vogel, A. B., "BNT162b vaccines protect rhesus macaques from SARS-CoV-2", Nature, 592, pp.283~289 (2021)
72. Lederer, K., "SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation", Immunity, 53, pp.1281~1295 (2020)
73. Laczko, D., "A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2in mice", Immunity, 53, pp.724~732 (2020)
74. Anderson, E. J., "Safety and immunogenicity of SARS-CoV-2 mRNA-1273vaccine in older adults", N. Engl. J. Med, 383, pp.2427~2438 (2020)
75. Painter, M. M., "Rapid induction of antigen-specific CD4(+)T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination", Immunity, 54, pp.2133~2142 (2021)
76. Sahin, U., "COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses", Nature, 586, pp.594~599 (2020)
77. Sahin, U., "BNT162b2 vaccine induces neutralizing antibodies and polyspecific T cells in humans", Nature, 595, pp.572~577 (2021)
78. Bettini, E., "SARS-CoV-2 mRNA vaccines : Immunological mechanism and beyond", Vaccines(Basel), 9, pp.147~ (2021)
79. Tarke, A., "Impact of SARS-CoV-2 variants on the total CD4(+)and CD8(+)T cell reactivity in infected or vaccinated individuals", Cell Rep. Med, 2, pp.100355~ (2021)
80. Takano, T., "Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine", Cell Rep. Med, 3, pp.100631~ (2022)
81. Anand, P., "Review the safety of Covid-19 mRNA vaccines : a review", Patient Saf. Surg, 15, pp.20~ (2021)
82. Moreira, E. D. Jr, "Safety and efficacy of a third dose of BNT162b2 Covid-19vaccine", N. Engl. J. Med, 386, pp.1910~1921 (2022)
83. Fraiman, J., "Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults", Vaccine, 40, pp.5798~5805 (2022)
84. Li, L. L., "Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination : a nationwide, retrospective cohort study", Vaccine, 40, pp.1082~1089 (2022)
85. Repajic, M., "Bell’s Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell’s palsy", Brain Behav. Immun. Health, 13, pp.100217~ (2021)
86. Caminati, M., "Who is really at risk for anaphylaxis due to COVID-19 vaccine?", Vaccines(Basel), 9, pp.38~ (2021)
87. Barda, N., "Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting", N. Engl. J. Med, 385, pp.1078~1090 (2021)
88. Abu Lila, A. S., "The accelerated blood clearance(ABC)phenomenon : clinical challenge and approaches to manage", J. Control Release, 172, pp.38~47 (2013)
89. Heil, F., "Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8", Science, 303, pp.1526~1529 (2004)
90. Hou, X., "Lipid nanoparticles for mRNA delivery", Nat. Rev. Mater, 6, pp.1078~1094 (2021)
91. Kariko, K., "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability", Mol. Ther, 16, pp.1833~1840 (2008)
92. Estape Senti, M., "Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement", J. Control Release, 341, pp.475~486 (2022)
93. Alameh, M. G., "Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses", Immunity, 55, pp.1136~1138 (2022)
94. Kobiyama, K, "Making innate sense of mRNA vaccine adjuvanticity", Nat. Immunol, 23, pp.474~476 (2022)
95. Tahtinen, S., "IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines", Nat. Immunol, 23, pp.532~542 (2022)
96. Liu, Y., "Effects of engineered nanoparticles on the innate immune system", Semin. Immunol, 34, pp.25~32 (2017)
97. Pham, C. T., "Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces", J. Biol. Chem, 286, pp.123~130 (2011)
98. Vlatkovic, I., "Non-immunotherapy application of LNP-mRNA : Maximizing efficacy and safety", Biomedicines, 9, pp.530~ (2021)
99. Kozma, G. T., "Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nanobiopharmaceuticals", Adv. Drug Deliv. Rev, 154–155, pp.163~175 (2020)
100. Szebeni, J., "Complement activation-related pseudoallergy : a stress reaction in blood triggered by nanomedicines and biologicals", Mol. Immunol, 61, pp.163~173 (2014)
101. Malone, R. W., "Cationic liposome-mediated RNA transfection", Proc. Natl Acad. Sci. USA, 86, pp.6077~6081 (1989)
102. Wang, Y., "Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy", Mol. Ther, 21, pp.358~367 (2013)
103. Broudic, K., "Nonclinical safety evaluation of a novel ionizable lipid for mRNA delivery", Toxicol. Appl. Pharmacol, 451, pp.116143~ (2022)
104. Lonez, C., "Cationic lipids activate intracellular signaling pathways", Adv. Drug Deliv. Rev, 64, pp.1749~1758 (2012)
105. Lonez, C., "Cationic lipid nanocarriers activate Toll-like receptor 2 and NLRP3inflammasome pathways", Nanomedicine, 10, pp.775~782 (2014)
106. Lonez, C., "Critical residues involved in Toll-like receptor 4 activation by cationic lipid nanocarriers are not located at the lipopolysaccharide-binding interface", Cell Mol. Life Sci, 72, pp.3971~3982 (2015)
107. Kedmi, R., "The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation", Biomaterials, 31, pp.6867~6875 (2010)
108. Abrams, M. T., "Evaluation of efficacy, biodistribution, and inflammation for a potent siRNA nanoparticle : effect of dexamethasone co-treatment", Mol. Ther, 18, pp.171~180 (2010)
109. Malamas, A. S., "Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery", J. Control Release, 171, pp.296~307 (2013)
110. Sun, D., "Structure and function of cationic and ionizable lipids for nucleic acid delivery", Pharm. Res, 40, pp.27~46 (2023)
111. Ganesan, P., "Recent developments in solid lipid nanoparticle and surface-modified solid lipid nanoparticle delivery systems for oral delivery of phyto-bioactive compounds in various chronic diseases", Int. J. Nanomed, 13, pp.1569~1583 (2018)
112. Ferraresso, F., "Comparison of DLin-MC3-DMA and ALC-0315 for siRNA delivery to hepatocytes and hepatic stellate cells", Mol. Pharm, 19, pp.2175~2182 (2022)
113. Kim, J., "Self-assembled mRNA vaccines", Adv. Drug Deliv. Rev, 170, pp.83~112 (2021)
114. Halamoda-Kenzaoui, B., "Main trends of immune effects triggered by nanomedicines in preclinical studies", Int. J. Nanomed, 13, pp.5419~5431 (2018)
115. Milla, P., "PEGylation of proteins and liposomes : a powerful and flexible strategy to improve the drug delivery", Curr. Drug Metab, 13, pp.105~119 (2012)
116. Richter, A. W., "Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins", Int. Arch. Allergy Appl. Immunol, 70, pp.124~131 (1983)
117. Ju, Y., "Anti-PEG antibodies boosted in humans by SARS-CoV-2 lipid nanoparticle mRNA vaccine", ACS Nano, 16, pp.11769~11780 (2022)
118. Kiaie, S. H., "Recent advances in mRNA-LNP therapeutics : immunological and pharmacological aspects", J. Nanobiotechnol, 20, pp.276~ (2022)
119. Szebeni, J., "Hemodynamic changes induced by liposomes and liposomeencapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody", Circulation, 99, pp.2302~2309 (1999)
120. Hoang Thi, T. T., "The Importance of poly(ethylene glycol)alternatives for overcoming peg immunogenicity in drug delivery and bioconjugation", Polym. (Basel), 12, pp.298~ (2020)
121. Kariko, K., "Suppression of RNA recognition by Toll-like receptors : the impact of nucleoside modification and the evolutionary origin of RNA", Immunity, 23, pp.165~175 (2005)
122. Sahin, U., "mRNA-based therapeutics—developing a new class of drugs", Nat. Rev. Drug Discov, 13, pp.759~780 (2014)
123. Kariko, K., "Generating the optimal mRNA for therapy : HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA", Nucleic Acids Res, 39, pp.e142~ (2011)
124. Schlake, T., "mRNA as novel technology for passive immunotherapy", Cell Mol. Life Sci, 76, pp.301~328 (2019)
125. Thess, A., "Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals", Mol. Ther, 23, pp.1456~1464 (2015)
126. Kon, E., "Principles for designing an optimal mRNA lipid nanoparticle vaccine", Curr. Opin. Biotechnol, 73, pp.329~336 (2022)
127. Rosa, S. S., "C. mRNA vaccines manufacturing: Challenges and bottlenecks", Vaccine, 39, pp.2190~2200 (2021)
128. Wouters, O. J., "Challenges in ensuring global access to COVID-19 vaccines : production, affordability, allocation, and deployment", Lancet, 397, pp.1023~1034 (2021)

관련 논문AI추천